The renowned American magazine Forbes has made inconsistent statements regarding cryptocurrencies. In a report published last year, Forbes labeled 20 altcoins, including $XRP, Cardano (ADA), Litecoin (LTC), and Ethereum Classic (ETC), as “zombies.”

However, he now includes some altcoins, which he describes as zombie tokens, among the top 10 cryptocurrencies to invest in.

According to Forbes’ latest updates, $XRP has been included in their list of the top 10 cryptocurrencies to invest in, ranking fourth after Bitcoin, Ethereum, and $BNB.

Forbes states that the list was compiled based on criteria such as real-world use, market capitalization, and trading volume, and only assets with a market capitalization exceeding $5 billion were included.

Accordingly, the list includes projects such as Solana, TRON, Hyperliquid, Rain, UNUS SED LEO, and Zcash (ZEC), in addition to Bitcoin, Ethereum $BNB, and $XRP.

Bitcoin tops the list with its status as digital gold, while Ethereum comes in second thanks to its power in smart contracts and decentralized applications.

Forbes highlighted $XRP’s role in international payments as one of its greatest strengths, noting that Ripple has forged partnerships with financial institutions, providing $XRP with a practical use case that sets it apart from many other cryptocurrencies.

Conversely, it was also noted that $XRP has disadvantages. The first of these was concerns about centralization, while the other was the large $XRP holdings of Ripple co-founder Chris Larsen.

“…Unlike Bitcoin and other cryptocurrencies obtained through mining, $XRP tokens enter circulation the moment Ripple decides to sell coins. Therefore, there are concerns about the centralized structure controlling the $XRP supply.”

Ripple co-founder Chris Larsen, with a net worth ranging from $1 to $7.6 billion, owns a significant portion of $XRP.

2- There are concerns about centralization due to Ripple’s control over the $XRP supply.

$XRP, with a market capitalization of $67 billion, is currently trading at around $1.07.

*This is not investment advice.